CA3240392A1 - Alz-801 for use in treating alzheimer's disease - Google Patents
Alz-801 for use in treating alzheimer's disease Download PDFInfo
- Publication number
- CA3240392A1 CA3240392A1 CA3240392A CA3240392A CA3240392A1 CA 3240392 A1 CA3240392 A1 CA 3240392A1 CA 3240392 A CA3240392 A CA 3240392A CA 3240392 A CA3240392 A CA 3240392A CA 3240392 A1 CA3240392 A1 CA 3240392A1
- Authority
- CA
- Canada
- Prior art keywords
- alz
- day
- subject
- dosage
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287552P | 2021-12-09 | 2021-12-09 | |
| US63/287,552 | 2021-12-09 | ||
| PCT/US2022/052331 WO2023107658A1 (en) | 2021-12-09 | 2022-12-09 | Alz-801 for use in treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3240392A1 true CA3240392A1 (en) | 2023-06-15 |
Family
ID=85157530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3240392A Pending CA3240392A1 (en) | 2021-12-09 | 2022-12-09 | Alz-801 for use in treating alzheimer's disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041248A1 (enExample) |
| EP (1) | EP4444286A1 (enExample) |
| JP (1) | JP2024542844A (enExample) |
| KR (1) | KR20240116529A (enExample) |
| CN (1) | CN118678950A (enExample) |
| AU (1) | AU2022405026A1 (enExample) |
| CA (1) | CA3240392A1 (enExample) |
| IL (1) | IL313404A (enExample) |
| MX (1) | MX2024007070A (enExample) |
| WO (1) | WO2023107658A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3347002T (pt) * | 2015-09-10 | 2023-07-27 | Alzheon Inc | Tratamento de doença de alzheimer numa população particular de pacientes |
| DK3829563T3 (en) * | 2018-08-01 | 2025-02-24 | Alzheon Inc | 3-sulfopropanoic acid for treating neurodegenerative disorders |
-
2022
- 2022-12-09 IL IL313404A patent/IL313404A/en unknown
- 2022-12-09 MX MX2024007070A patent/MX2024007070A/es unknown
- 2022-12-09 CN CN202280091217.0A patent/CN118678950A/zh active Pending
- 2022-12-09 WO PCT/US2022/052331 patent/WO2023107658A1/en not_active Ceased
- 2022-12-09 EP EP22851094.7A patent/EP4444286A1/en active Pending
- 2022-12-09 US US18/717,139 patent/US20250041248A1/en active Pending
- 2022-12-09 CA CA3240392A patent/CA3240392A1/en active Pending
- 2022-12-09 JP JP2024534268A patent/JP2024542844A/ja active Pending
- 2022-12-09 AU AU2022405026A patent/AU2022405026A1/en active Pending
- 2022-12-09 KR KR1020247022383A patent/KR20240116529A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022405026A1 (en) | 2024-06-20 |
| JP2024542844A (ja) | 2024-11-15 |
| EP4444286A1 (en) | 2024-10-16 |
| IL313404A (en) | 2024-08-01 |
| WO2023107658A1 (en) | 2023-06-15 |
| US20250041248A1 (en) | 2025-02-06 |
| KR20240116529A (ko) | 2024-07-29 |
| CN118678950A (zh) | 2024-09-20 |
| MX2024007070A (es) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5289765B2 (ja) | 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用 | |
| Shopsin et al. | Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients | |
| Perry et al. | Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up | |
| Graziano et al. | Dose-response study of oral 2, 3-dimercaptosuccinic acid in children with elevated blood lead concentrations | |
| US20250339450A1 (en) | Treatment of syngap1 encephalopathy | |
| TW201900158A (zh) | 使用氟苯丙胺治療杜希氏徵候群之方法 | |
| Sydenstricker et al. | The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders | |
| KR20170036116A (ko) | 간성 뇌병증의 치료방법 | |
| Perry et al. | Clinical study of mianserin, imipramine and placebo in depression: blood level and MHPG correlations. | |
| AU2021281118A1 (en) | Treatment of autism spectrum disorder with cannabidiol | |
| CN104582793A (zh) | 用拉喹莫德和氨吡啶的组合治疗多发性硬化症 | |
| US20250041248A1 (en) | Alz-801 for use in treating alzheimer's disease | |
| Hollander et al. | Pharmacologic approaches in the treatment of pathological gambling | |
| JUDAH et al. | Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz) | |
| JP2024508860A (ja) | 認知機能障害の処置のためのルバダキシスタットの使用 | |
| AU2021404023A1 (en) | Use of mglur5 antagonists for treating gambling disorder | |
| Haq et al. | Bipolar disorder and tuberous sclerosis complex: is it a mere coincidence? | |
| Tariot et al. | Anticonvulsants to treat agitation in dementia | |
| STOTSKY et al. | A controlled study of the efficacy of pentylenetetrazol (Metrazol) with hard-core hospitalized psychogeriatric patients | |
| JP2007532624A (ja) | アルツハイマー病の治療のための療法組合せ | |
| DOWNIE et al. | Hypoglycaemic sulphonamides in the management of diabetes mellitus | |
| CN121942892A (zh) | 一种用于神经保护和认知功能改善的组合物和制备方法及其用途 | |
| CN117580576A (zh) | Luvadaxistat用于治疗认知损害的用途 | |
| HK40026552A (en) | Methods of treating doose syndrome using fenfluramine | |
| Pohlmann-Eden et al. | Understanding Antiepileptic Drugs: Guiding You Through the Maze of Options |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241126 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241126 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251201 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251201 |